Literature DB >> 2025261

Fusogenic activity of SIV (simian immunodeficiency virus) peptides located in the GP32 NH2 terminal domain.

I Martin1, F Defrise-Quertain, V Mandieau, N M Nielsen, T Saermark, A Burny, R Brasseur, J M Ruysschaert, M Vandenbranden.   

Abstract

Peptides of 12, 16 and 24 amino acids length corresponding to the NH2 terminal sequence of SIV gp32 were synthesized. Fluorescence energy transfer studies have shown that those peptides can induce lipid mixing of SUV (Small Unilamellar Vesicles) of various compositions at pH 7.4 and 37 degrees C. LUV (Large Unilamellar Vesicles) were shown to undergo fusion, provided they contained PE in their lipid composition. This work is an attempt to determine how the fusogenic activity depends on the structure of the peptide inserted into a lipidic environment. The peptides secondary structure and orientation in the lipid bilayer were determined using Fourier Transform infrared spectroscopy (FTIR). They adopt mainly a beta-sheet conformation in the absence of lipids. After interaction with DOPC SUV, the beta-sheet is partly converted into alpha-helix oriented obliquely with respect to the membrane interface. We bring here evidence that this oblique orientation is a prerequisite to the fusion process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025261     DOI: 10.1016/0006-291x(91)91646-t

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Membrane structure of the human immunodeficiency virus gp41 fusion domain by molecular dynamics simulation.

Authors:  Shantaram Kamath; Tuck C Wong
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

2.  Distribution of hydrophobic residues is crucial for the fusogenic properties of the Ebola virus GP2 fusion peptide.

Authors:  B Adam; L Lins; V Stroobant; A Thomas; R Brasseur
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.

Authors:  M Pritsker; P Jones; R Blumenthal; Y Shai
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

4.  Reversible surface aggregation in pore formation by pardaxin.

Authors:  D Rapaport; R Peled; S Nir; Y Shai
Journal:  Biophys J       Date:  1996-06       Impact factor: 4.033

5.  "De novo" design of peptides with specific lipid-binding properties.

Authors:  L Lins; B Charloteaux; C Heinen; A Thomas; R Brasseur
Journal:  Biophys J       Date:  2005-11-04       Impact factor: 4.033

6.  Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer.

Authors:  I Martin; H Schaal; A Scheid; J M Ruysschaert
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Correlation between fusogenicity of synthetic modified peptides corresponding to the NH2-terminal extremity of simian immunodeficiency virus gp32 and their mode of insertion into the lipid bilayer: an infrared spectroscopy study.

Authors:  I Martin; M C Dubois; F Defrise-Quertain; T Saermark; A Burny; R Brasseur; J M Ruysschaert
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Structure and orientation of apo B-100 peptides into a lipid bilayer.

Authors:  L Lins; R Brasseur; M Rosseneu; C Y Yang; D A Sparrow; J T Sparrow; A M Gotto; J M Ruysschaert
Journal:  J Protein Chem       Date:  1994-01

9.  Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells.

Authors:  V Vonèche; D Portetelle; R Kettmann; L Willems; K Limbach; E Paoletti; J M Ruysschaert; A Burny; R Brasseur
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Theoretical and functional analysis of the SIV fusion peptide.

Authors:  M Horth; B Lambrecht; M C Khim; F Bex; C Thiriart; J M Ruysschaert; A Burny; R Brasseur
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.